新型生物制剂在关节病型银屑病中的应用  

Novel biologics in treatment of psoriatic arthritis

作　　者：周炯[1] 郑敏[1] 

机构地区：[1]浙江大学医学院附属第二医院皮肤科,浙江杭州310009

出　　处：《浙江大学学报（医学版）》2009年第4期404-408,共5页Journal of Zhejiang University(Medical Sciences)

摘　　要：关节病型银屑病是一种与银屑病相关的炎性关节病。该疾病早期诊断困难,而且缺乏有效药物;晚期患者可出现关节强直而致残,甚至死亡。传统药物在阻止关节损害方面效果不佳,毒副作用大。新型生物制剂作为一种基于银屑病发病机制中的免疫关键步骤而研发的新药,为关节病型银屑病的治疗提供了较为有效的方案。Psoriatic arthritis is an inflammatory joint disease associated with psoriasis. Due to difficulty for early diagnosis and lack of effective therapy,the disease leads to chronic course and frequent relapse. Patients may suffer from ankylosis, disability and even death. The past treatments neither can control the disease effectively,nor be capable of inhibiting the development of structural joint damage. Based on the current psoriasis pathogenesis,novel biologics have been developed, which can aim the specific targets, resulting in more effective and safer management for psoriatic arthritis.

关 键 词：关节炎 牛皮癣/药物疗法 生物制品 关节病型银屑病 治疗 生物制剂 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]